Boxes of tablets, produced by Novartis Ag, sit on the pharmacy meter.
Bloomberg Bloomberg Gety pictures
The Swiss drug company Novartis said on Thursday that it expects the treatment of breast cancer to be the next drug next within its wallet, as it looks to convert dependence away from the treatment of heart failure.
The company said in the sales report in the second quarter that sales of Kisaqali, which treats metastatic breast cancer, increased by 64 % on the basis of a fixed currency in the three months to June. It includes 100 % growth in the United States
A 56 % increase in Kisqali sales is followed in the first quarter to March.
Speaking in a call call, the CEO of Vas Narasimhan said that Kisqali was the medicine that exceeded the performance.
The diagnoses and death of global breast cancer will increase by 2050, according to the World Health Organization Cancer AgencyWith 1 in every 20 women around the world, breast cancer is expected to be diagnosed in their lives.
This can be translated into 3.2 million new cases and 1.1 million deaths annually all over the world by 2050 in the event of continued current trends, the study-much higher than 2.3 million new cases and 670,000 cases.
Narasimhan also cited a “strong pipeline” for Novartis from other drugs, including the treatment of Pluvicto and Scemblix for chronic spinal leukemia, which he also said “on the right path to be detailed.”
He added in a statement accompanying the results, “We are still continuing to lead a strong performance on our continuous launch of Kisqali, Pluvicto and Scemblix, which indicates the power of replacement in our wallet,” he added in a statement accompanying the results.
The comments come at a time when Novartis seeks to get rid of its dependence on Enterreso, which faces the expiration of patents next year. Entesto achieved $ 7.8 billion in 2024, which represents about 15 % of the company’s total global sales.
On Thursday, he said that they are expected from public drug makers to start producing copies of the drug by mid -2015, although this timeline “is subject to the continuous IP (intellectual property) and organizational litigation.”
On Wednesday, an American federal judge refused to request Novartis Preliminary To prevent MSN Pharmaceuticals from selling a general version of the drug before the patent has expired.
Entesto sales increased by 22 % in the second quarter, in line with the previous three months.
“It is an important product for us,” said Harry Kirch, outgoing financial manager, on Thursday.
He added: “We have the IP address that we are defending. If we are successful in defending our attractiveness, every month we will have some gentle upward trend.”
In general, the net sales of the second quarter of Novartis increased by 11 % on the basis of a fixed currency to 14.05 billion dollars, only shy of $ 14.18 billion, estimated by analysts in the LSEG survey.
Meanwhile, semester basic operating income increased by 21 % to $ 5.93 billion, slightly higher than $ 5.69 billion.
Novartis said she is now expecting the basic operating income for the whole year through “low teenagers”, with an increase of “Low Double Digit” previously, while keeping her expectations for sales growth in high individual numbers.
The company also announced the re -purchase of shares of up to 10 billion dollars, indicating “confidence” in its growth in the middle and long -term.
https://image.cnbcfm.com/api/v1/image/108173325-1752757690774-gettyimages-630649566-UK_PHARMA.jpeg?v=1752757717&w=1920&h=1080
2025-07-17 13:10:00
